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Summary. Peripheral neuropathy is an important and 
disabling side-effect of cisplatin treatment. A new drug, 
Org 2766, has been found to prevent his neuropathy up 
to 1 month after treatment. A group of 18 patients with 
ovarian cancer, who participated in an earlier andomized 
study with placebo or Org 2766, together with cisplatin 
and cyclophophamide, were thereafter prospectively fol- 
lowed up to 2 years after discontinuation of treatment to 
monitor the development of neurological signs and symp- 
toms and vibration perception threshold (VPT). Explor- 
atory, descriptive data analysis hows that between 1and 
4 months after the last cycle the average sum score for 
neurological signs and symptoms and VPT had deterior- 
ated compared with 1 month after treatment. Thereafter 
a gradual but incomplete improvement was seen between 
4-12 and 12-24 months after treatment. These changes 
were seen in all patients regardless of previous treatment 
with Org 2766 or placebo, but deterioration was less 
pronounced in patients previously treated with Org 2766. 
These results suggests that treatment with Org 2766 to 
prevent a cisplatin-induced neuropathy should possibly 
be continued up to 4 months after the last cycle of cispla- 
tin. 
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Introduction 
Cisplatin has proved to be an effective anti-cancer drug, 
particularly in the treatment of ovarian and testicular 
cancer. A well-known major and dose-limiting side-ef- 
fect of cisplatin is a peripheral neuropathy [1, 5, 8, 9, 10, 
12, 13, 15]. The incidence and severity of this side-effect 
is clearly related to the total cumulative dose of cisplatin 
administered. Cisplatin-induced polyneuropathy is char- 
acterized by a sensory neuropathy, due to damage of 
large myelinated la fibres, probably at the level of the 
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dorsal root ganglion cell [15]. The polyneuropathy is
only reversible in some patients, but accurate informa- 
tion on the natural history after cessation of cisplating 
treatment is not available. 
A new drug, Org 2766, an ACTH analogue, has been 
found in a recent study to be able to prevent he neurop- 
athy when given concomitantly with cisplatin [4, 6]. A 
group of 18 patients who participated in that study have 
been followed to monitor the course of neuropathic signs 
and symptoms after discontinuation of treatment with 
cisplatin and Org 2766. Our observations are reported 
here. 
Materials and methods 
All patients participated in a multi-centre double-blind, placebo- 
controlled randomized trial in which treatment with cisplatin was 
combined with two different doses of Org 2766 or placebo [6]. 
Women eligible for this study had a histologically verified epithe- 
lial ovarian carcinoma, FIGO stage III or IV. Exclusion criteria 
were: age over 70 years, previous chemotherapy, established clini- 
cal or subclinical neuropathy, diabetes mellitus, alcohol abuse, 
brain involvement or leptomeningeal disease, or inadequate bone 
marrow, liver or renal function. Patients receiving vitamin B sup- 
plements or other vitamin diets were also excluded. Performance 
status according to the World Health Organization scale had to be 
2 or better, that is less than 50% of normal day-time hours spent in 
bed. 
Chemotherapy consisted of cyclophosphamide (750mg/m 2)
and cisplatin (75 mg/m 2) every 3 weeks, up to a maximum of nine 
cycles if possible. 
Org 2766 was injected subcutaneously before the start of 
cisplating administration and 24 h later. It was administered in a 
low (0.25mg/m 2) or high (lmg/m 2) dose. An equal amount of 
mannitol served as placebo. The results during treatment until 
after the sixth cycle of cisplatin in this multic-centre study have 
been reported [6]. Thereafter, patients from our hospital were fol- 
lowed and examined in the neurology clinic for neuropathic signs 
and symptoms and vibration threshold. Seven of 25 participating 
patients from our institution were not eligible for further follow-up 
because of progressive disease or death before the sixth cycle. In 
the remaining 18 patients examinations were performed within 1 
month after the last cycle, between i and 4 months, between 4 and 
12 months and between 12 and 24 months after the last cycle of 
cisplatin. 
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Table 1. Correlation coefficients between eurological signs and 
symptoms and vibration perception threshold (VPT). Correlation 
coefficients (r) based on a total of 75 observations in 18 patients 
Log VPT Sum I Sum II Sum III 
Log VPT 1.00 
Sum I 0.75 1.00 
II 0.73 0.67 1.00 
III 0.81 0.88 0.94 1.00 
Table 2. Number of observations in each time period, n, Number 
of patients in each group 
Before i month i -4  4-12 12-24 
treat- after months months months 
ment treat- after after after 
(n) ment treat treat treat 
(n) ment ment ment 
(n) (n) (n) 
All patients 18 12 13 16 9 
Placebo 7 6 5 6 4 
Org low 5 4 3 4 2 
Org high 6 2 5 6 3 
All patients had to answer a questionnaire with regard to the 
presence of absence of paraesthesias, numbness, loss of strength, 
loss of dexterity, unstaediness of gait, pain and Lhermitte's sign. 
Various tests, including sense of pain, fine touch, vibration sense, 
Romberg's ign and straight line walking heel-to-toe, patellar and 
Achilles tendon reflexes were performed and scored as abnormal 
or normal. 
Separate sum scores were calculated for symptoms (sum score 
I; minimum O, maximum 6), signs (sum score II; minimum O, 
maximum 10) and sum score III, being the total of sum scores I 
and II. 
In all patients the threshold of vibration perception (VPT) was 
measured by Vibrameter Type III (Somedic, Stockholm, Sweden) 
on the second metacarpal bone of the left hand, expressed in 
micromillimetres [7]. 
No a priori hypothesis about the further course of neuropathy 
after cessation of treatment was specified. Therefore the analysis 
was primarily exploratory, aiming at a description of the level of 
neuropathy as a function of time after treatment. This was achieved 
by calculation of the mean values of VPT and sum scores in four 
periods after treatment. Formal tests for significance were not per- 
formed because of the limited number of patients and the explora- 
tory character of the study. 
Results 
The average number  of cycles was 6.9 (SD 1.3), with 6.4 
(SD 1.3) in the p lacebo group (n = 7), 7.0 (SD 1.4) in the 
low-dose Org group (n = 5) and 7.3 (SD 1.4) cycles in 
the high-dose Org group (n = 6). This corresponds to a 
cumulat ive dose of  cisplatin of  518 mg/m 2 for the whole 
group and 480 mg/m 2 for p lacebo,  550mg/m 2 for low- 
dose, and 570 mg/m 2 cisplatin for h igh-dose Org. 
Corre lat ion coefficients between vibrat ion threshold 
and sum scores of signs and symptoms based on all avail- 
able mult ip le observat ions of the pat ients were 0.67 or 
higher (Table 1). 
The total  number  of pat ients at each point  in t ime is 
given in Table  2, showing that between 9 and 16 single 
observat ions were recorded in each t ime per iod.  As all 
pat ients had part ic ipated in a randomized ouble-b l inded 
trial with p lacebo or low or high-dose Org 2766, the ta- 
bles also include data on each of these subgroups. The 
main emphasis ,  however,  will be on the combined re- 
sults with or without Org 2766 after discont inuat ion of  
t reatment  with cisplatin and cyc lophosphamide.  
Table 3 lists the sum scores of neurological  signs and 
symptoms and average of VPT over t ime. Between 1 and 
Table 3. Course of sum scores of neurologi- 
cal signs and symptoms and VPT over time. 
Sum I indicates the average sum score (SD) 
of neurological symptoms, um II of 
neurological signs and sum III the total of 
sum scores I and II. The VPT values repre- 
sent the geometrical mean (SD) 
Before 1 month 1-4 4-12 12-24 
treatment after months months months 
(n = 18) treatment after after after 
(n = 12) treatment treatment treatment 
(n -- 13) (n = 16) (n = 9) 
Sum I in all patients 0 2.4 (2.3) 3.3 (1.9) 2.5 (1.8) 1.3 (1.6) 
Placebo - 2.5 3.5 3.3 2.3 
Org low - 3.5 4.7 2.3 0.5 
Org high - 0.0 2.2 2.0 0.7 
Sum II in all patients 0 2.8 (2.9) 4.0 (3.5) 2.2 (2.1) 1.1 (1.7) 
Placebo - 3.8 3.8 2.5 2.3 
Org low - 2.8 6.3 2.5 0.0 
Org high - 0.0 2.8 1.6 0.3 
Sum III in all patients 0 5.3 (4.7) 7.2 (4.8) 4.6 (3.6) 2.0 (2.9) 
Placebo - 6.3 7.2 5.7 4.0 
Org low - 6.3 11.0 4.5 0.5 
Org high - 0.0 5.0 3.5 1.0 
VPT in all patients 0.4 (0.3) 2.8 (2.9) 5.9 (7.0) 3.2 (4.4) 2.9 (1.1) 
Placebo 0.6 3.7 8.1 4.8 2.9 
Org low 0.5 2.9 14.6 3.6 0.6 
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Fig. 1. Average sum score III of neurological signs, symptoms and 
standard deviation for all patients 
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Sixteen patients had multiple observations in the first 
half-year after treatment. Sum score III deteriorated in 
this period in 6 patients and remained about he same in 
10 patients. The VPT deteriorated in 9 patients and re- 
mained on the same level in the other 7 patients. 
As in the multicentre study we can also observe here 
that patients receiving high-dose Org had better scores 
at 1 month after the last cycle than those treated with 
placebo r low-dose Org. Thereafter patients in all sub- 
groups deteriorated. Patients who had received high- 
dose Org showed less deterioration between 1 and 4 
months than the other two subgroups, although patients 
with low-dose Org did worse than patients who had re- 
ceived placebo, but numbers per subgroup were too 
small for statistical comparison (Table 3). Patients with 
high-dose Org had an average sum score for signs and 
symptoms of 0 at 1 month after treatment, 5.0 at 1-4 
months, 3.5 at 4-12 and 1.0 at 12-24 months after dis- 
continuation of treatment with cisplatin. To indicate the 
variation over time for individual patients, Fig. 3 shows 
the plots of VPT of patients previously treated with 
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Fig. 2. Average log vibration perception threshold and standard 
deviation for all patients 
4 months after the last cycle, neurological signs and 
symptoms and VPT further deteriorated in all patients 
compared with within 1 month after discontinuation f 
treatment. Between 4-12 months and 12-24 months after 
the last cycle, the neurological sum scores and VPT 
showed a gradual improvement, but values did not nor- 
malize. The time-course for the sum score of neurologi- 
cal signs and average log VPT is graphically shown in 
Figs. 1 and 2. To indicate the variation between indi- 
vidual patients, bars in these figures represent standard 
deviations and not standard errors of the mean. 
Discussion 
These results indicate that signs and symptoms of cispla- 
tin-induced neuropathy progressed after discontinuation 
of cisplatin for a period of about 4 months, followed by 
a spontaneous amelioration during the following 12-24 
months, but that they did not normalize. This pattern is 
evident for the VPT measurements and for the sum 
scores of signs and symptoms. The measurement of VPT 
compared with nerve conduction velocities has the ad- 
vantage that it can be recorded quantitavely and accu- 
rately without causing discomfort to the patient [3, 7, 
13]. It is also closely related to the severity of the clinical 
neuropathy asshown by high correlations with sum scores 
for signs and symptoms. 
We observed that patients previously treated with 
Org 2766 also deteriorated between i and 4 months after 
the last cycle. However, the numbers of observations in 
each subgroup reviously treated with placebo, high- or 
low-dose Org 2766 are too small to allow for statistical 
analysis and the differences between these groups could 
still be explained by chance variation. It is therefore pos- 
sible that the differences between the subgroups only re- 
flect the maximum damage incurred by cisplatin to sen- 
sory nerve function, rather than the effect of Org 2766. 
In a study of 30 patients treated with cisplatin, vin- 
blastine and bleomycin for germ cell cancer and exam- 
ined between 49 and 106 months after cessation of treat- 
ment [9], the majority of patients till had abnormal val- 
ues for VPT and nerve conduction velocities [9]. In two 
consecutive chemotherapy trials, neuropathy in any grade 
of toxicity developed in 47% of patients treated with a 
cisplatin-containing regimen. In patients who survived 
for more than 5 years, the incidence of cisplatin europ- 
athy was 61%. In a preliminary report, deterioration of
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Fig. 3. Changes in vibration perception 
threshold over time in individual patients 
previously treated with placebo, low-dose 
(0.25) or high-dose (ling) Org. On the 
X-axis the time-course isindicated by: 
0, pretreatment; 1, within 1 month after 
last cycle; 2, between 1and 4 months 
after last cycle; 3, between 4and 12 
months after last cycle; 4, between 12 and 
24 months after last cycle 
one-third of patients after cisplatin treatment followed 
by incomplete recovery [14]. 
MoUman et al. [11] described three cases of delayed 
peripheral neuropathy developing signs and symptoms 
3-8 weeks after completion of cisplating therapy, with a 
recovery in two patients after 8 and 27 months. 
In experimental animal studies, sensory nerve con- 
duction velocities improved considerably the first 15 
weeks after discontinuation of cisplain [4]. However, 
these studies were performed in young growing rats. 
Morphological studies have demonstrated that changes 
caused by cisplatin consist primarily of axonal damage 
with secondary demyelination [15]. With Org 2766 it 
has been found that it is possible to prevent he neuro- 
toxic effects of cisplatin [4, 6]. The mechanism of this ef- 
fect is however, unclear, but two hypotheses might be 
offered: (1.) protection, in which Org 2766 might pre- 
vent the directly toxic effect of cisplatin on the axon; (2.) 
repair, in which Org 2766 enhances the repair capacity 
of the axon [2]. 
The worsening of the polyneuropathy after discon- 
tinuation of cisplatin argues against he first hypothesis, 
as one would no expect progression if Org 2766 is a pro- 
tective drug. However, if Org 2766 enhances the repair 
capacities of the sensory neuron or axon, one might ex- 
pect a progression of the polyneuropathy after simul- 
taneous discontinuation of cisplatin and Org 2766. Our 
data, therefore, would support the repair mechanism 
hypothesis [2]. 
As we established in a previous study that high-dose 
Org 2766 could prevent he neuropathy when given con- 
comitantly with cisplatin [6] and we now found that after 
cessation of treatment a deterioration of sensory func- 
tion nevertheless developed between 1 and 4 months 
later, these observations would suggest hat administer- 
ing Org 2766 should be continued until the end of this 
period. 
In conclusion, our results show that deterioration of 
clinical signs and VPT in cisplatin-induced neuropathy 
continues during the first 4 months after cessation of 
cisplatin treatment. Subsequently, a gradual but incom- 
plete improvement is seen up to 2 years after treatment. 
The beneficial effect of the ACTH analogue Org 2766 
seems to be based on enhancing repair mechanisms rather 
than on preventing damaging effects of cisplatin on 
nerve fibres or dorsal root ganglion cells. 
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